

# Specialty Guideline Management

## Palsonify

### Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Palsonify	paltusotine

### Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

#### FDA-approved Indications<sup>1</sup>

Palsonify is indicated for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.

All other indications are considered experimental/investigational and not medically necessary.

### Documentation

Submission of the following information is necessary to initiate the prior authorization review:

- For initial approval: Laboratory report indicating high pretreatment insulin-like growth factor-1 (IGF-1) level and chart notes indicating an inadequate or partial response to surgery or a clinical reason for not having surgery.

Reference number(s)
7223-A

- For continuation: Laboratory report indicating normal current IGF-1 levels or chart notes indicating that the member's IGF-1 level has decreased or normalized since initiation of therapy.

## Coverage Criteria

### Acromegaly<sup>1-3</sup>

Authorization of 12 months may be granted for the treatment of acromegaly when all of the following criteria are met:

- Member has a high pretreatment IGF-1 level for age and/or gender based on the laboratory reference range.
- Member had an inadequate or partial response to surgery OR there is a clinical reason why the member has not had surgery.

## Continuation of Therapy

Authorization of 12 months may be granted for continuation of therapy for acromegaly when the member's IGF-1 level has decreased or normalized since initiation of therapy.

## References

1. Palsonify [package insert]. San Diego, CA: Crinetics Pharmaceuticals, Inc.; September 2025.
2. Katznelson L, Laws ER, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014; 99:3933-3951.
3. American Association of Clinical Endocrinologists Acromegaly Guidelines Task Force. Medical guidelines for clinical practice for the diagnosis and treatment of acromegaly – 2011 update. Endocr Pract. 2011;17(suppl 4):1-44.